Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · October 23, 2022

Mepolizumab in Urban Children With Exacerbation-Prone Eosinophilic Asthma in the US

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Lancet 2022 Aug 13;400(10351)502-511, DJ Jackson, LB Bacharier, PJ Gergen, L Gagalis, A Calatroni, S Wellford, MA Gill, J Stokes, AH Liu, RS Gruchalla, RT Cohen, M Makhija, GK Khurana Hershey, GT O'Connor, JA Pongracic, MG Sherenian, K Rivera-Spoljaric, EM Zoratti, SJ Teach, M Kattan, CM Dutmer, H Kim, C Lamm, WJ Sheehan, RM Segnitz, KA Dill-McFarland, CM Visness, PM Becker, JE Gern, CA Sorkness, WW Busse, MC Altman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading